Skip to main content

Table 2 Baseline Characteristics and TOP1 copy number

From: Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer

 

Total N (%)

TOP1 CN per cell

TOP1 CN per cell

Pearson Chi-Square test p

TOP1/CEN-20 ratio ≥ 2 N (%)

TOP1/CEN-20 ratio < 2 N (%)

Pearson Chi-Square test p

TOP1/CEN-2 ratio ≥ 2 N (%)

TOP1/CEN-2 ratio <  2 N (%)

Pearson Chi-Square test p

>median 4.46 No (%)

≤ median 4.46 No (%)

Patients included

108 (100)

54 (50)

54 (50)

 

10 (9)

98 (91)

 

58 (54)

50 (46)

 

Gender

Males

65 (60)

35 (54)

30 (46)

0.33

6 (9)

59 (91)

0.99

37 (57)

28 (43)

0.41

Females

43 (40)

19 (44)

24 (56)

4 (9)

39 (91)

21 (49)

22 (51)

Age

≥65

52

23 (44)

29 (56)

0.25

4 (8)

48 (92)

0.59

26 (50)

26 (50)

0.46

<65

56

31 (55)

25 (45)

6 (11)

50 (89)

32 (57)

24 (43)

WHO PS

0

51 (47)

25 (49)

26 (51)

0.99

5 (10)

46 (90)

0.95

25

26

0.33

1–2

53 (49)

26 (49)

27 (51)

5 (9)

48 (91)

31

22

unknowna

4 (4)

         

Location primary tumor

Right

24 (22)

13 (54)

11 (46)

0.82

1 (4)

23 (96)

0.36

10 (42)

14 (58)

0.32

Left

43 (40)

22 (51)

21 (49)

6 (14)

37 (86)

23 (53)

20 (47)

Rectum

41 (38)

19 (46)

22 (54)

3 (7)

38 (93)

25 (61)

16 (39)

Primary tumor resected

Yes

98 (91)

48 (49)

50 (51)

0.51

7 (7)

91 (93)

0.02

51 (52)

47 (48)

0.28

No

10 (9)

6 (60)

4 (40)

3 (30)

7 (70)

7 (70)

3 (30)

Number of metastatic sites

1

37 (34)

17 (46)

20 (54)

0.78

3 (8)

34 (92)

0.87

22 (59)

15 (41)

0.14

2

35 (33)

19 (54)

16 (46)

4 (11)

31 (89)

14 (40)

21 (60)

>2

36 (33)

18 (50)

18 (50)

3 (8)

33 (92)

22 (61)

14 (39)

Prior chemotherapy

F

10 (9)

7 (70)

3 (30)

0.10

3 (30)

7 (70)

0.054

9 (90)

1 (10)

0.01

F + Oxa

95 (88)

47 (49)

48 (51)

7 (7)

88 (93)

49 (52)

46 (48)

F + Oxa + Bev

3 (3)

0 (0)

3 (100)

0 (0)

3 (100)

0 (0)

3 (100)

Prior radiotherapy

Yes

5 (5)

2 (40)

3 (60)

0.65

0 (0)

5 (100)

0.47

4 (80)

1 (20)

0.23

No

103 (95)

52 (50)

51 (50)

10 (10)

93 (90)

54 (52)

49 (48)

Liver metastases

Yes

80 (74)

43 (54)

37 (46)

0.19

8 (10)

72 (90)

0.65

43 (54)

37 (46)

0.99

No

28 (26)

11 (39)

17 (61)

2 (7)

26 (93)

15 (54)

13 (46)

Lung metastases

Yes

46 (43)

25 (54)

21 (46)

0.44

3 (7)

43 (93)

0.40

24 (52)

22 (48)

0.78

No

62 (57)

29 (47)

33 (53)

7 (11)

55 (89)

34 (55)

28 (45)

  1. Abbreviations: CN Copy number, F Fluorouracil (5-FU), Oxa Oxaliplatin, Bev Bevacizumab, HR Hazard ratio, CI Confidence interval